Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Afatinib vs Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma After Platinum Based Chemotherapy
A randomised, open-label, Phase III study to evaluate the efficacy and safety of oral afatinib* vs intravenous (IV) methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based therapy.
Trial CT.gov-Identifier: NCT01856478
Histologically/cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, which has recurred/metastasised and is not amenable to salvage surgery or radiotherapy
Documented progressive disease following a cisplatin- and/or carboplatin- and/or nedaplatin-based regimen
Eastern Cooperative Oncology Group performance status 0–1
Primary outcome measure:
Secondary outcome measures:
LUX-Head & Neck 3, initiated in May 2013, is the equivalent of the LUX-Head & Neck 1 trial in Asian patients. This trial is currently recruiting participants; participating countries include China, Taiwan, Egypt, Hong Kong, India, Korea, Philippines and Thailand.
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT01856478 (Accessed: July 2017).
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information. Afatinib is being investigated in urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue